Could Your Antidepressant Be Affecting Your Sex Life Long After You Stop Taking It?

May 20, 2026:

Could Your Antidepressant Be Affecting Your Sex Life Long After You Stop Taking It?

For many women, antidepressants like Prozac, Lexapro, Zoloft, and Effexor can be life-changing. But for some, the sexual side effects don’t disappear after the medication ends. This condition is known as Post-SSRI Sexual Dysfunction (PSSD) and while it’s still underrecognized, awareness is growing.

PSSD refers to persistent sexual symptoms that continue months or even years after stopping an SSRI or SNRI antidepressant. Women may experience reduced libido, genital numbness, difficulty becoming aroused, vaginal dryness, muted orgasms, or complete inability to orgasm.

What Makes PSSD Different?

Sexual side effects while actively taking antidepressants are extremely common. In fact, studies suggest that SSRIs can affect desire, arousal, and orgasm in a significant percentage of women taking them.

What makes PSSD different is that symptoms persist after the medication has been discontinued.

Many women describe feeling “disconnected” from their sexuality or frustrated that their mental health improved while their sexual function never fully returned. Unfortunately, these symptoms are sometimes dismissed as anxiety, relationship stress, or depression itself, leaving patients feeling unheard.

Symptoms of PSSD in Women

Common symptoms may include:

Low or absent sexual desire
Reduced genital sensation or numbness
Difficulty with arousal
Vaginal dryness
Delayed, weak, or absent orgasms
Emotional disconnect during intimacy

Symptoms can vary widely from woman to woman, and there is currently no specific lab test that confirms PSSD. Diagnosis is based largely on medical history and symptom patterns.

Is PSSD Rare?

Researchers still do not know exactly how common PSSD is. Some women recover quickly after stopping antidepressants, while others continue to struggle long term. Experts agree that more research is needed, but major medical organizations and recent studies increasingly recognize that persistent sexual dysfunction after SSRIs is real.

What Can Be Done?

There is no universal “cure” for PSSD, but treatment may help improve symptoms. At Maze Women’s Health, evaluation often includes looking at:

Hormonal balance
Blood flow and nerve sensitivity
Medication history
Pelvic health
Emotional and relationship impact

Because female sexual function is complex, treatment usually requires a personalized approach rather than a one size fits all solution.

The Bottom Line

If your sexual function changed after taking antidepressants, and never fully returned, you are not imagining it. PSSD is a real and distressing condition that deserves thoughtful medical evaluation and compassionate care.

The good news? You do not have to struggle in silence. Awareness around PSSD is growing, and more women are finally getting the support and validation they deserve.

Take the next steps, schedule a consultation with Maze Women’s Health.

Source link

tags

Abkhazia Afghanistan Africa Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Central African Republic Chad Chile China Colombia Comoros Costa Rica Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France French Polynesia Gabon Gambia Georgia Germany Ghana Greece Grenada Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea North Macedonia Northern Cyprus Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Republic of the Congo Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Korea South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Transnistria Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda UK Ukraine United Arab Emirates Uruguay USA Uzbekistan Vanuatu Vatican City Venezuela Vietnam Western Sahara Yemen Zambia Zimbabwe